BDBM516979 N-(3-fluoro-4-((3-((1- hydroxy-4-methoxybutan- 2-yl)amino)-1H- pyrazolo[3,4-b]pyridin-4- yl)oxy)phenyl)-2-(4- fluorophenyl)-3-oxo-2,3- dihydropyridazine-4- carboxamide::US11104676, Example 192::US11104676, Example 193::US11104676, Example 49

SMILES COCCC(CO)Nc1n[nH]c2nccc(Oc3ccc(NC(=O)c4ccnn(-c5ccc(F)cc5)c4=O)cc3F)c12

InChI Key InChIKey=ATCZLUUQARELRC-UHFFFAOYSA-N

Data  27 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 27 hits for monomerid = 516979   

TargetHepatocyte growth factor receptor [F1200I](Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [Y1230S](Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 1.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [Y1230H](Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 3.90nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [Y1230C](Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 1.90nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [L1195V](Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 45nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [F1200I](Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 2.40nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [D1228N](Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 3.70nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [D1228H](Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 4.90nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [1-13,15-1390](Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 2.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [Y1230S](Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 9.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [Y1230H](Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 17.4nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [Y1230C](Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 9.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [L1195V](Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 263nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 2.20E+3nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [D1228N](Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 10.2nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [D1228H](Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 39.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [1-13,15-1390](Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 19.2nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor TYRO3(Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 1.21E+4nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 6.50E+3nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 2.20E+3nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor TYRO3(Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 6.14E+4nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 1.08E+4nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 3.50E+3nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor TYRO3(Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 2.39E+4nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM516979(US11104676, Example 49 | N-(3-fluoro-4-((3-((1- hy...)
Affinity DataIC50: 5.80E+3nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent